Twist Bioscience Corporation TWST Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 52.1%+0.4pp | 51.6%+0.9pp | 50.7%+1.5pp | 49.2%+2.5pp | 46.7%+2.1pp | |
| Operating margin | -33.9%+0.5pp | -34.4%+1.8pp | -36.2%+3.1pp | -39.3%+18.6pp | -57.9%+5.3pp | |
| Net margin | -19.8%-0.3pp | -19.6%+1.1pp | -20.6%+2.9pp | -23.5%+31.5pp | -55%+4.8pp | |
| EBITDA margin | -27.9%+0.2pp | -28.1%+1.5pp | -29.6%+2.7pp | -32.3%+17.6pp | -49.9%+4.3pp | |
| Free cash flow margin | -23.2%-1.1pp | -22.1%-2.1pp | -20.1%-1.1pp | -19%-0.1pp | -18.8%+1.9pp | |
| Returns | ||||||
| Return on equity | -18.2%-1.4pp | -16.8%-0.4pp | -16.4%+1.1pp | -17.6%+20.6pp | -38.2%-0.5pp | |
| Return on assets | -12.8%-0.5pp | -12.3%+0.1pp | -12.4%+0.9pp | -13.3%+16.1pp | -29.4%0.0pp | |
| Return on invested capital | -36.4%-0.4pp | -36%+2.6pp | -38.6%+1.9pp | -40.5%+15.0pp | -55.4%+0.7pp | |
| Efficiency | ||||||
| Asset turnover | 0.6×0.0× | 0.6×0.0× | 0.6×0.0× | 0.6×0.0× | 0.5×0.0× | |
| Inventory turnover | 7.2×+0.5× | 6.7×-0.4× | 7.1×+0.3× | 6.8×-0.5× | 7.2×+0.5× | |
| Liquidity | ||||||
| Current ratio | 2.7×-1.1× | 3.8×+0.1× | 3.6×-0.3× | 3.9×-0.6× | 4.5×-0.4× | |
| Quick ratio | 2.4×-1.0× | 3.4×0.0× | 3.3×-0.3× | 3.6×-0.6× | 4.2×-0.4× | |
| Cash ratio | 1×-0.8× | 1.9×-0.2× | 2×-0.3× | 2.3×-0.5× | 2.8×-0.4× | |
| Leverage | ||||||
| Debt-to-equity | 0.2×0.0× | 0.2×+0.1× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | |
| Debt-to-assets | 0.2×0.0× | 0.2×0.0× | 0.1×0.0× | 0.1×0.0× | 0.2×0.0× | |
| Per Share | ||||||
| Book value per share | $7.38-1.2% | $7.47-5.6% | $7.91+1.1% | $7.82+6.0% | $7.38-4.3% | |
| Valuation | ||||||
| Market capitalization | $2.91B+50.2% | $1.94B+14.2% | $1.7B-20.9% | $2.15B-8.3% | $2.34B-15.1% | |
| Enterprise value | $2.9B+52.5% | $1.9B+18.6% | $1.6B-21.3% | $2.04B-8.4% | $2.22B-15.5% | |
| Price / sales | 7.1×+2.2× | 5×+0.4× | 4.5×-1.4× | 5.9×-0.8× | 6.7×-1.6× | |
| Price / book | 6.4×+2.1× | 4.3×+0.7× | 3.6×-0.9× | 4.5×-0.8× | 5.3×-0.7× | |
| EV / sales | 7.1×+2.2× | 4.9×+0.6× | 4.3×-1.4× | 5.6×-0.8× | 6.4×-1.6× | |
| Free cash flow yield | -3.3%+1.2pp | -4.5%0.0pp | -4.5%-1.3pp | -3.2%-0.4pp | -2.8%-0.3pp | |
| Earnings yield | -2.8%+1.2pp | -3.9%+0.6pp | -4.6%-0.6pp | -4%+4.2pp | -8.2%-1.0pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Twist Bioscience Corporation's profit margins?
- Twist Bioscience Corporation (TWST) runs a 52.1% gross margin and a -33.9% operating margin, with a -19.8% net margin.
- Where do Twist Bioscience Corporation's ratios come from?
- Every ratio is computed from Twist Bioscience Corporation's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
